SCYNEXIS INC
About SCYNEXIS INC
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $20.6M
- Net income
- -$8.6M
- Total assets
- $59.0M
- Market cap
- $46.8M
- Operating margin
- -78.0%
- Net margin
- -41.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $20.6M
- Operating expenses
- $36.7M
- Operating income
- -$16.1M
- Income tax
- $0
- Net income
- -$8.6M
- EPS (basic)
- $-0.17
- EPS (diluted)
- $-0.17
Balance sheet
- Total assets
- $59.0M
- Current assets
- $40.4M
- Total liabilities
- $9.7M
- Current liabilities
- $5.7M
- Shareholders’ equity
- $49.4M
Cash flow
- Operating cash flow
- -$5.3M
- Investing cash flow
- $24.3M
- Financing cash flow
- -$14.2M
- Net cash flow
- $4.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $46.8M
- EPS (diluted)
- $-0.17
- Shares outstanding
- 11.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 2, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.6M in FY2025.
- Revenue grew 57% from FY2021 to FY2025.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SCYNEXIS INC.
Write a review
News about SCYNEXIS INC
News & sentiment via Polygon.io
